The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.

The firm said that investors provided better-than-expected backing as the company anticipates growing use of its digital pathology platform in 2025.

The aggregate repurchase authorization program now totals $200 million, which the firm will fund with cash and cash equivalents.

The purchase includes the manufacturing process of four ELISA kits, two of which are in vitro diagnostic products for specialty diagnostics and disease monitoring.

The Switzerland-based firm's MosaiQ AiPlex Connective Tissue Diseases (CTDplus) assay is used to aid the diagnosis of autoimmune diseases.

NEW YORK – With the launch of its first product, a rule-out test for pancreatic cysts that can help risk-stratify patients who may have pancreatic cancer, Purdue University spinout Amplified Sciences ...

The firm's next-generation sequencing-based test detects single nucleotide variants, insertions, and deletions in 22 genes.

Of the 30 companies, three saw their stock prices increase, 26 saw their share prices decline, and one company's share price remained virtually flat month over month.

NEW YORK — ABL Diagnostics said on Wednesday that it has signed an agreement for the distribution of its infectious disease molecular assays in India with Genient Tech Private.

The firm said that it has received approval for a test that combines the Allsheng-developed Auto-Pure 2400 liquid handling platform with Revvity's T-SPOT.TB test.

The automated DxC 500 I analyzer has a throughput of up to 800 clinical chemistry tests and 100 immunoassays per hour.

The ruling makes clear that the FDA lacks the legal authority to regulate LDTs, and observers suggest it could also call into question its authority in other areas.